Bass J, Freeman J B, Makarewicz P, Sproule P, Fairfull-Smith R
Can J Surg. 1985 Mar;28(2):124-5.
Thirty patients who received routine intravenous therapy (3.3% dextrose and 0.3% normal saline at a rate of 100 mL/h) were randomized prospectively into two groups to receive an antiphlebitic mixture of heparin-hydrocortisone-sodium bicarbonate or placebo in a double-blinded fashion for 4 to 7 days. The code was then broken and the data were analysed using chi 2 analysis with respect to the clinical grade and incidence of phlebitis. Phlebitis developed in 2 of 14 study and 10 of 16 control patients. All study patients tolerated their intravenous lines longer and needed less restarting. The antiphlebitic mixture effectively prevented superficial infusion phlebitis in patients receiving dextrose-saline solutions.
30名接受常规静脉治疗(100 mL/h的3.3%葡萄糖和0.3%生理盐水)的患者被前瞻性随机分为两组,以双盲方式接受肝素 - 氢化可的松 - 碳酸氢钠的抗静脉炎混合物或安慰剂治疗4至7天。然后揭开盲法编码,使用卡方分析对静脉炎的临床分级和发生率进行数据分析。14名研究组患者中有2名发生静脉炎,16名对照组患者中有10名发生静脉炎。所有研究组患者的静脉留置时间更长,重新置管的需求更少。抗静脉炎混合物有效预防了接受葡萄糖 - 盐水溶液患者的浅表性输液静脉炎。